Evidence map›Paper›PMID 31931492›Full record

ArticlePhysical biology2020

Studying nanoscale structural alterations in cancer cells to evaluate ovarian cancer drug treatment, using transmission electron microscopy imaging.

Prakash Adhikari, Mehedi Hasan, Vijayalakshmi Sridhar, Debarshi Roy, Prabhakar Pradhan

Open access · greenAbstract read
In one paragraph

Article in Physical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Prakash AdhikariDepartment of Physics and Astronomy, Mississippi State University, Mississippi State, MS 39762, United States of America.
Mehedi HasanDepartment of Physics and Astronomy, Mississippi State University, Mississippi State, MS 39762, United States of America.
Vijayalakshmi SridharDepartment of Experimental Pathology, Mayo Clinic College of Medicine, Rochester, MN 39096, United States of America.
Debarshi RoyDepartment of Biology, Alcorn State University, Lorman, MS 55905, United States of America.
Prabhakar PradhanDepartment of Physics and Astronomy, Mississippi State University, Mississippi State, MS 39762, United States of America.ORCID 0000-0003-4363-2326
Mississippi State University · USAlcorn State University · USMayo Clinic · US

Funding

Training and Mentoring Core P20GM103476 · NIGMS · UNIVERSITY OF SOUTHERN MISSISSIPPI · PI MICHAEL R GARRETT · 2012 to 2026
$60.2M
High-throughput molecular-specific cell nanocytology for cancer screeningR01EB016983 · NIBIB · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM, SUBRAMANIAN, HARIHARAN · 2013 to 2016
$1.3M
NIBIB NIH HHS R01 EB016983NIGMS NIH HHS P20 GM103476
6 · The paper itself

Abstract

Understanding nanoscale structural changes can provide information about the physical state of cells/tissues. It has now been shown that increases in nanoscale structural alterations are associated with the progress of carcinogenesis in most cancer cases, including early carcinogenesis. Anti-cancerous therapies are designed to inhibit the growth of cancer cells; however, it is challenging to detect the efficacy of such drugs in the early stages of treatment. A unique method of assessing the impact of anti-cancerous drugs on cancerous cells/tissues is to probe the nanoscale structural alterations. In this paper, we study the effect of different anti-cancerous drugs on ovarian tumorigenic cells, using their nanoscale structural alterations as a biomarker. Transmission electron microscopy (TEM) imaging on thin cell sections is performed to obtain their nanoscale structures. The degree of nanoscale structural alterations of tumorigenic cells and anti-cancerous drug treated tumorigenic cells are quantified by using the recently developed inverse participation ratio (IPR) technique. Results show an increase in the degree of nanoscale fluctuations in tumorigenic cells relative to non-tumorigenic cells; then a near-reversal of the degree of fluctuation in tumorigenic cells to that in non-tumorigenic cells, following anti-cancerous drug treatment. These results support that the effect of anti-cancerous drugs in cancer treatment can be quantified by using the degree of nanoscale fluctuations in the cells via TEM imaging. Potential applications of the technique for cancer treatment are also discussed.

Indexed as

Optical ImagingAntineoplastic AgentsCell LineFemaleHumansMicroscopy, Electron, TransmissionNanostructuresNanotechnologyOvarian NeoplasmsAntineoplastic Agents

Identifiers

PMID31931492
PMCPMC7346740
OpenAlexW2999438082

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.